ReviewJournal of clinical medicine2026

Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.

Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.